

RNAi for Therapeutic-Asia Pacific Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/RDD50B33706EN.html>

Date: February 2018

Pages: 130

Price: US\$ 3,480.00 (Single User License)

ID: RDD50B33706EN

Abstracts

Report Summary

RNAi for Therapeutic-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on RNAi for Therapeutic industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of RNAi for Therapeutic 2013-2017, and development forecast 2018-2023

Main market players of RNAi for Therapeutic in Asia Pacific, with company and product introduction, position in the RNAi for Therapeutic market

Market status and development trend of RNAi for Therapeutic by types and applications

Cost and profit status of RNAi for Therapeutic, and marketing status

Market growth drivers and challenges

The report segments the Asia Pacific RNAi for Therapeutic market as:

Asia Pacific RNAi for Therapeutic Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China

Japan

Korea

India

Southeast Asia

Australia

Asia Pacific RNAi for Therapeutic Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

siRNA
miRNA
shRNA

Asia Pacific RNAi for Therapeutic Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Cancer
Cardiovascular
HBV
Other

Asia Pacific RNAi for Therapeutic Market: Players Segment Analysis (Company and
Product introduction, RNAi for Therapeutic Sales Volume, Revenue, Price and Gross
Margin):

Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead Research
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
Miragen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Arcturus Therapeutics
Ariz Biopharma
Celsion Corporation
Asclepis Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF RNAI FOR THERAPEUTIC

- 1.1 Definition of RNAi for Therapeutic in This Report
- 1.2 Commercial Types of RNAi for Therapeutic
 - 1.2.1 siRNA
 - 1.2.2 miRNA
 - 1.2.3 shRNA
- 1.3 Downstream Application of RNAi for Therapeutic
 - 1.3.1 Cancer
 - 1.3.2 Cardiovascular
 - 1.3.3 HBV
 - 1.3.4 Other
- 1.4 Development History of RNAi for Therapeutic
- 1.5 Market Status and Trend of RNAi for Therapeutic 2013-2023
 - 1.5.1 Asia Pacific RNAi for Therapeutic Market Status and Trend 2013-2023
 - 1.5.2 Regional RNAi for Therapeutic Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of RNAi for Therapeutic in Asia Pacific 2013-2017
- 2.2 Consumption Market of RNAi for Therapeutic in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of RNAi for Therapeutic in Asia Pacific by Regions
 - 2.2.2 Revenue of RNAi for Therapeutic in Asia Pacific by Regions
- 2.3 Market Analysis of RNAi for Therapeutic in Asia Pacific by Regions
 - 2.3.1 Market Analysis of RNAi for Therapeutic in China 2013-2017
 - 2.3.2 Market Analysis of RNAi for Therapeutic in Japan 2013-2017
 - 2.3.3 Market Analysis of RNAi for Therapeutic in Korea 2013-2017
 - 2.3.4 Market Analysis of RNAi for Therapeutic in India 2013-2017
 - 2.3.5 Market Analysis of RNAi for Therapeutic in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of RNAi for Therapeutic in Australia 2013-2017
- 2.4 Market Development Forecast of RNAi for Therapeutic in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of RNAi for Therapeutic in Asia Pacific 2018-2023
 - 2.4.2 Market Development Forecast of RNAi for Therapeutic by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Asia Pacific Market Status by Types

- 3.1.1 Consumption Volume of RNAi for Therapeutic in Asia Pacific by Types
- 3.1.2 Revenue of RNAi for Therapeutic in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in China
 - 3.2.2 Market Status by Types in Japan
 - 3.2.3 Market Status by Types in Korea
 - 3.2.4 Market Status by Types in India
 - 3.2.5 Market Status by Types in Southeast Asia
 - 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of RNAi for Therapeutic in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of RNAi for Therapeutic in Asia Pacific by Downstream Industry
- 4.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of RNAi for Therapeutic by Downstream Industry in China
 - 4.2.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in Japan
 - 4.2.3 Demand Volume of RNAi for Therapeutic by Downstream Industry in Korea
 - 4.2.4 Demand Volume of RNAi for Therapeutic by Downstream Industry in India
 - 4.2.5 Demand Volume of RNAi for Therapeutic by Downstream Industry in Southeast Asia
 - 4.2.6 Demand Volume of RNAi for Therapeutic by Downstream Industry in Australia
- 4.3 Market Forecast of RNAi for Therapeutic in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF RNAI FOR THERAPEUTIC

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 RNAi for Therapeutic Downstream Industry Situation and Trend Overview

CHAPTER 6 RNAI FOR THERAPEUTIC MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

- 6.1 Sales Volume of RNAi for Therapeutic in Asia Pacific by Major Players
- 6.2 Revenue of RNAi for Therapeutic in Asia Pacific by Major Players
- 6.3 Basic Information of RNAi for Therapeutic by Major Players
 - 6.3.1 Headquarters Location and Established Time of RNAi for Therapeutic Major Players

- 6.3.2 Employees and Revenue Level of RNAi for Therapeutic Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 RNAI FOR THERAPEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Alnylam Pharmaceuticals

- 7.1.1 Company profile
- 7.1.2 Representative RNAi for Therapeutic Product
- 7.1.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals

7.2 Arbutus Biopharma (Tekmira)

- 7.2.1 Company profile
- 7.2.2 Representative RNAi for Therapeutic Product
- 7.2.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arbutus Biopharma (Tekmira)

7.3 Arrowhead Research

- 7.3.1 Company profile
- 7.3.2 Representative RNAi for Therapeutic Product
- 7.3.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arrowhead Research

7.4 Dicerna Pharmaceuticals

- 7.4.1 Company profile
- 7.4.2 Representative RNAi for Therapeutic Product
- 7.4.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals

7.5 Mirna Therapeutics

- 7.5.1 Company profile
- 7.5.2 Representative RNAi for Therapeutic Product
- 7.5.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Mirna Therapeutics

7.6 Quark Pharmaceuticals

- 7.6.1 Company profile
- 7.6.2 Representative RNAi for Therapeutic Product
- 7.6.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Quark Pharmaceuticals

7.7 RXi Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative RNAi for Therapeutic Product

7.7.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of RXi

Pharmaceuticals

7.8 Silence Therapeutics

7.8.1 Company profile

7.8.2 Representative RNAi for Therapeutic Product

7.8.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silence

Therapeutics

7.9 Benitec Biopharma

7.9.1 Company profile

7.9.2 Representative RNAi for Therapeutic Product

7.9.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Benitec

Biopharma

7.10 Miragen Therapeutics

7.10.1 Company profile

7.10.2 Representative RNAi for Therapeutic Product

7.10.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Miragen

Therapeutics

7.11 Sylentis

7.11.1 Company profile

7.11.2 Representative RNAi for Therapeutic Product

7.11.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sylentis

7.12 Gradalis

7.12.1 Company profile

7.12.2 Representative RNAi for Therapeutic Product

7.12.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Gradalis

7.13 Sirnaomics

7.13.1 Company profile

7.13.2 Representative RNAi for Therapeutic Product

7.13.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sirnaomics

7.14 Silenseed

7.14.1 Company profile

7.14.2 Representative RNAi for Therapeutic Product

7.14.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silenseed

7.15 Arcturus Therapeutics

7.15.1 Company profile

7.15.2 Representative RNAi for Therapeutic Product

7.15.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arcturus
Therapeutics

7.16 Ariz Biopharma

7.17 Celsion Corporation

7.18 Ascleitis Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RNAI FOR THERAPEUTIC

8.1 Industry Chain of RNAi for Therapeutic

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF RNAI FOR THERAPEUTIC

9.1 Cost Structure Analysis of RNAi for Therapeutic

9.2 Raw Materials Cost Analysis of RNAi for Therapeutic

9.3 Labor Cost Analysis of RNAi for Therapeutic

9.4 Manufacturing Expenses Analysis of RNAi for Therapeutic

CHAPTER 10 MARKETING STATUS ANALYSIS OF RNAI FOR THERAPEUTIC

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: RNAi for Therapeutic-Asia Pacific Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/RDD50B33706EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RDD50B33706EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970